ANTEROS PHARMACEUTICALS
Anteros Pharmaceuticals is a biotechnology company that develops drugs for fibrotic and other inflammatory diseases. Anteros is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement.
Similar Organizations
Emergency MCG
EMCG is a medical device and diagnostic services company saving lives through accurate, early, and inexpensive measurement of heart disease.
FreeShakes
FreeShakes uses biotechnological processes to reduce fructose and other simple sugars from natural fruits.
Fustibal
Fustibal is a biotechnology startup that develops antibody-based nanomedicines for multi-targeted cancer therapy.
Imbioray
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases.
Pieris AG
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and so on.
Sunol Molecular
A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.
Virotek Biosciences
Virotek Biosciences is a biotech company that provides on-site products for rapid diagnostics and emerging infectious diseases.
Xalud Therapeutics
Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases.
More informations about "Anteros Pharmaceuticals"
BioMotiv and Bristol-Myers Squibb announce the Launch of …
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement. Anteros will focus on refining a new …See details»
Anteros Pharmaceuticals - Crunchbase Company Profile & Funding
Anteros Pharmaceuticals is a biotechnology company that develops drugs for fibrotic and other inflammatory diseases. Anteros is the first of several companies that BioMotiv and Bristol …See details»
BMS, BioMotiv alliance generates biopharma company …
Feb 5, 2020 Its first company launch was Oxford, UK-based biotech Orca Pharmaceuticals back in 2013, which is working on RORγ inhibitors for the …See details»
BMS and BioMotiv launch Anteros Pharmaceuticals
Feb 4, 2020 BMS has an option to acquire Anteros from BioMotiv after the company identifies a pre-clinical candidate. BioMotiv CEO Satish Jindal said: …See details»
Anteros Pharmaceuticals - VentureRadar
Anteros Pharmaceuticals was launched by Bristol-Myers Squibb and partner BioMotiv, a biopharma accelerato. Itis investigating a new class of drugs? with intellectual property …See details»
BioMotiv and Bristol-Myers Squibb Launch Anteros Pharma
Feb 4, 2020 BioMotiv, a drug development accelerator, and Bristol-Myers Squibb jointly launched Anteros Pharmaceuticals. Anteros will focus on developing a new class of drugs for …See details»
Bristol-Myers Squibb, BioMotiv launch new firm …
BMS and BioMotiv have launched a new biotechnology company, Anteros Pharmaceuticals, which new class of drugs for fibrotic and other inflammatory …See details»
Anteros Pharmaceuticals - Drug pipelines, Patents, Clinical trials ...
Jan 3, 2025 Last update 01 Nov 2024. Anteros Pharmaceuticals. Private CompanySee details»
Anteros Pharmaceuticals - Crunchbase
Anteros Pharmaceuticals is a biotechnology company that develops drugs for fibrotic and other inflammatory diseases. New. Resources. Advanced Search. …See details»
BioMotiv and Bristol-Myers Squibb Announce the …
Feb 4, 2020 “Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic …See details»
BMS and BioMotiv launch first biotech firm - Chemical
Bristol-Myers Squibb and the drug-development accelerator BioMotiv have launched Anteros Pharmaceuticals, a biotech firm developing drugs for fibrosis and inflammatory diseases. The …See details»
BioMotiv and BMS launch Anteros Pharmaceuticals
Once Anteros nominates a pre-clinical candidate, Bristol-Myers Squibb has the option to acquire the company from BioMotiv under pre-agreed terms. Satish Jindal, Ph.D., BioMotiv’s CEO …See details»
BioMotiv, Bristol-Myers Squibb launch Anteros Pharmaceuticals
Feb 6, 2020 Anteros Pharmaceuticals is a new biotechnology company created by Bristol-Myers Squibb and BioMotiv. The new company plans to focus on a new class of drugs for fibrotic and …See details»
Anteros - Products, Competitors, Financials, Employees, …
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the strategic partnership agreement. Anteros will focus on refining a new …See details»
BioMotiv and Bristol-Myers Squibb Launch Anteros Pharma
Feb 4, 2020 BioMotiv, by forming Anteros and working with Yale, will be solely responsible for research and development. “Anteros Pharmaceuticals is the first of several companies that …See details»
New Biotech Company to Focus on Unmet Medical Needs
Feb 5, 2020 The launch of a biotechnology company, called Anteros Pharmaceuticals, was announced on Tuesday. The company is a collaboration between BioMotiv and Bristol- Myers …See details»
Anteros enters the market powered by BioMotiv and Bristol-Myers …
Once Anteros nominates a pre-clinical candidate, BMS has the option to acquire the company from BioMotiv under pre-agreed terms. “Anteros Pharmaceuticals is the first of several …See details»
Bristol-Myers launches biotech targeting fibrosis, inflammation
Feb 4, 2020 Dive Brief: Bristol-Myers Squibb and partner BioMotiv, a biopharma accelerator, launched Tuesday a new company focused on creating inflammation and fibrosis medicines. …See details»
BioMotiv and Bristol-Myers Squibb announce the launch of …
Feb 4, 2020 "Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement. Anteros will focus on …See details»
Bristol-Myers forms fibrotic disease biotech, bags buyout option
Feb 4, 2020 The biotech, Anteros Pharmaceuticals, starts life with materials from Bristol-Myers to support development of small molecules and the potential to land a takeover by the Big …See details»